Advertisement


Michael J. Overman, MD, and John Marshall, MD, on Metastatic Colorectal Cancer: Interim Results of the CheckMate 142 Trial

2016 ASCO Annual Meeting

Advertisement

Michael J. Overman, MD, of the University of Texas MD Anderson Cancer Center, and John Marshall, MD, of Georgetown University Lombardi Comprehensive Cancer Center, discuss interim findings on nivolumab with or without ipilimumab in the treatment of patients with metastatic colorectal cancer with and without high microsatellite instability (Abstract 3501).



Related Videos

Breast Cancer

Julie Lemieux, MD, on Letrozole in Postmenopausal Early-Stage Breast Cancer: Patient-Reported Outcomes (French Language)

Julie Lemieux, MD, of Centre Hospitalier Universitaire de Québec, discusses in French patient-reported outcomes from a study extending adjuvant letrozole for 5 years after completing an initial 5 years of aromatase inhibitor therapy alone or preceded by tamoxifen (Abstract LBA506). 

 To see the English language version of this video, please click here.

Issues in Oncology

Lee S. Schwartzberg, MD, on Progress of the Institute for Clinical Immuno-Oncology

Lee S. Schwartzberg, MD, of The West Clinic, reports on progress of the now year-old ACCC initiative to speed adoption of immunotherapeutics in community practices.

Issues in Oncology

Eric Roeland, MD, and Timothy E. Quill, MD, on the Debate Over Physician-Assisted Death

Eric Roeland, MD, of the University of California, San Diego, and Timothy E. Quill, MD, of the University of Rochester Medical Center, discuss the debate on whether physician-assisted death should be a legally available option at the end of life when neither palliative nor hospice care is satisfactory.

Global Cancer Care

Rakesh Chopra, MD, and Mary Gospodarowicz, MD, on The Indian Perspective of the Current State of Cancer Research and Treatment

Rakesh Chopra, MD, of the Artemis Health Institute, and Mary Gospodarowicz, MD, of Princess Margaret Hospital, discuss oncology from an international point of view.

Issues in Oncology

Maria Clemence Schwaederle, PharmD, on Precision Medicine: Its Impact in Refractory Malignancies

Maria Clemence Schwaederle, PharmD, of the University of California, San Diego, discusses an analysis of 13,203 patients in phase I clinical trials, which showed that a personalized strategy led to improved response rate and progression-free survival (Abstract 11520).

Advertisement

Advertisement




Advertisement